Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
29
Recruiting, any sponsor type, condition "acne"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed475
29 trials
Showing 1 to 25, recently updated first.
- Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)Pivotal-lookingRecruiting
Sagimet Biosciences Inc.Industry
NCT07863193 · 800 participants (planned) · Start Oct 21, 2026 · Primary completion Aug 2027
Drug: Denifanstat · For: Acne Vulgaris
Sites: Bryant, Arkansas; Beverly Hills, California; Fremont, California · 35 sites in all
Jeisys Medical IncIndustry
NCT07805655 · 60 participants (planned) · Start Sep 15, 2026 · Primary completion Dec 25, 2026
Drug: Adapalene 0.1% and Benzoyl Peroxide 2.5% gel · For: Acne Vulgaris
Sites: Nuevo León, Mexico
- Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe AcnePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07756957 · 410 participants (planned) · Start Oct 14, 2026 · Primary completion Jul 19, 2028
Drug: Acne mRNA (messenger ribonucleic acid) vaccine; Placebo · For: Acne
Sites: Edmonton, Canada; Vancouver, Canada · 3 sites in all
Incyte CorporationIncyte (INCY)
NCT07213973 · 40 participants (planned) · Start Feb 2, 2026 · Primary completion Mar 25, 2028
Drug: Povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Farmington, Connecticut · 28 sites in all
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07830329 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 24, 2028
Drug: Olatorepatide; Placebo · For: Hidradenitis Suppurativa
Sites: The Bronx, New York
- Finasteride and CutibacteriumRecruiting
University of WashingtonAcademic, hospital or other
NCT07731802 · 40 participants (planned) · Start Aug 31, 2026 · Primary completion Mar 31, 2027
Drug: Finasteride 5 mg; Placebo Control · For: Dihydrotestosterone; Periprosthetic Joint Infection (PJI); Cutibacterium Acnes
Sites: Seattle, Washington
IR INNOVATE RESEARCH PRIVATE LIMITEDIndustry
NCT07918001 · 225 participants (planned) · Start Feb 25, 2026 · Primary completion Feb 28, 2027
Drug: Klenzit®-C (Adapalene/Clindamycin Phosphate Gel) · For: Acne
Sites: Hanoi, Vietnam; Ho Chi Minh City, Vietnam · 3 sites in all
- Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate AcnePivotal-lookingRecruiting
Nishtar Medical UniversityAcademic, hospital or other
NCT07915648 · 158 participants (planned) · Start Sep 17, 2026 · Primary completion Mar 16, 2027
Drug: nadifloxacin; Tretinoin Cream 0.025% and 1 more · For: Acne Vulgaris
Sites: Multan, Pakistan
- Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne VulgarisPivotal-lookingRecruiting
Eurofarma Laboratorios S.A.Industry
NCT06905210 · 531 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 2027
Drug: Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg); Placebo · For: Acne Vulgaris; Acne Vulgaris on the Face
Sites: Salvador, Brazil; Brasília, Brazil; Goiânia, Brazil · 18 sites in all
- Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne VulgarisPivotal-lookingRecruiting
Pak Emirates Military HospitalAcademic, hospital or other
NCT07883538 · 130 participants (planned) · Start Oct 8, 2026 · Primary completion Apr 30, 2027
Drug: Clascoterone 1% cream; Adapalene 0.1% cream · For: Acne Vulgaris
Sites: Rawalpindi, Pakistan
- Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without AcnePivotal-lookingRecruiting
Sagimet Biosciences Inc.Industry
NCT06989840 · 152 participants (planned) · Start Jun 3, 2025 · Primary completion Jan 2027
Drug: TVB-3567; Placebo · For: Acne
Sites: Tempe, Arizona; Botany, Australia; Darlinghurst, Australia · 6 sites in all
- Facial Skin Microbiome in Patients With Moderate-to-Severe Acne Vulgaris Treated With IsotretinoinRecruiting
Can Tho University of Medicine and PharmacyAcademic, hospital or other
NCT07834138 · 90 participants (planned) · Start Jan 13, 2026 · Primary completion Feb 7, 2027
Drug: ISOtretinoin 10 MG · For: Acne Vulgaris
Sites: Can Tho, Vietnam
- Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color PatientsPivotal-lookingRecruiting
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
NCT06447480 · 420 participants (planned) · Start Apr 29, 2025 · Primary completion Sep 1, 2027
Drug: ISOtretinoin 5 MG; Topical cream · For: Acne Vulgaris
Sites: Nice, France; Bordeaux, France; Nantes, France · 19 sites in all
Zagazig UniversityGovernment (non-federal)
NCT07523217 · 52 participants (planned) · Start Mar 15, 2026 · Primary completion Mar 15, 2027
Drug: injectable PLLA; PLLA threads · For: Atrophic Acne Scarring
Sites: Zagazig, Egypt
- Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe AcnePivotal-lookingRecruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06316297 · 800 participants (planned) · Start Apr 5, 2024 · Primary completion Nov 30, 2028
Drug: Acne mRNA vaccine · For: Acne
Sites: Scottsdale, Arizona; Cerritos, California; Encino, California · 94 sites in all
Bausch Health Americas, Inc.Industry
NCT07524946 · 100 participants (planned) · Start Apr 1, 2026 · Primary completion Dec 2027
Drug: CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%. · For: Acne Vulgaris
Sites: Bryant, Arkansas; Rogers, Arkansas; Freemont, California · 15 sites in all
- Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild AcnePivotal-lookingRecruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT07013747 · 228 participants (planned) · Start Jul 3, 2025 · Primary completion Jun 19, 2029
Drug: Acne mRNA vaccine · For: Acne
Sites: Encino, California; Brandon, Florida; Jacksonville, Florida · 4 sites in all
- Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint InfectionsPivotal-lookingRecruiting
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
NCT05902221 · 235 participants (planned) · Start May 2, 2024 · Primary completion May 2028
Drug: amoxicillin or moxifloxacin; amoxicillin or moxifloxacin + rifampicin · For: Infections Joint Prosthetic
Sites: Annecy, France; Bordeaux, France; Boulogne, France · 13 sites in all
Medical University of South CarolinaAcademic, hospital or other
NCT06225570 · 50 participants (planned) · Start Feb 1, 2025 · Primary completion Mar 2027
Drug: Isotretinoin; Tetracycline · For: Acne Vulgaris
Sites: Charleston, South Carolina
Université de MontréalAcademic, hospital or other
NCT02996656 · 88 participants (planned) · Start Dec 2016 · Primary completion Dec 2026
Drug: Cefazolin; Ceftriaxone · For: Propionibacterium Infection
Sites: Montreal, Canada
Integrative Skin Science and ResearchIndustry
NCT07544251 · 30 participants (planned) · Start Apr 20, 2026 · Primary completion Apr 2027
Drug: Sarecycline; Doxycycline · For: Acne Vulgaris
Sites: Sacramento, California
- Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for AcnePivotal-lookingRecruiting
Shenzhen People's HospitalAcademic, hospital or other
NCT07366229 · 196 participants (planned) · Start Dec 30, 2025 · Primary completion Mar 30, 2026
Drug: MPN-coated engineered Lactobacillus reuteri cream; Plain Lactobacillus reuteri cream and 2 more · For: Acne
Sites: Shenzhen, China
Pham Ngoc Thach University of MedicineAcademic, hospital or other
NCT07474883 · 60 participants (planned) · Start Mar 9, 2026 · Primary completion Aug 9, 2026
Drug: Timolol 0.5% Ophthalmic Solution · For: Post Inflammtory Erythema; Acne Vulgaris; Erythema
Sites: Ho Chi Minh City, Vietnam
- Efficacy and Safety of Clascoterone Cream 1% in Facial Acne VulgarisPivotal-lookingRecruiting
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
NCT06403501 · 692 participants (planned) · Start May 20, 2024 · Primary completion Oct 2026
Drug: Clascoterone; Vehicle cream · For: Acne Vulgaris
Sites: Shanghai, China
Aswan UniversityAcademic, hospital or other
NCT07054398 · 60 participants (planned) · Start Jan 10, 2025 · Primary completion Jan 1, 2026
Drug: Isotretinoin · For: Acne Vulgaris
Sites: Aswān, Egypt
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.